You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 5,712,155


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,712,155
Title: DNA encoding tumor necrosis factor-.alpha. and -.beta. receptors
Abstract:Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Inventor(s): Smith; Craig A. (Seattle, WA), Goodwin; Raymond G. (Seattle, WA), Beckmann; M. Patricia (Poulsbo, WA)
Assignee: Immunex Corporation (Seattle, WA)
Application Number:08/346,555
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,712,155


Introduction

United States Patent 5,712,155 (hereafter "the '155 patent") was granted on February 24, 1998, and pertains to a novel method or composition within a specific technological field. As a critical piece of intellectual property, the '155 patent's claims define its scope of protection and influence subsequent innovation and patent filings. Analyzing both the patent claims and the surrounding patent landscape offers crucial insights into its strength, scope, potential for infringement, and its role within the broader technological ecosystem.

This article provides an in-depth evaluation of the '155 patent's claims, examines their limitations, explores relevant prior art, and situates the patent within the evolving patent landscape. The goal is to inform stakeholders—whether investors, patent practitioners, or competitors—about strategic considerations associated with this patent.


Overview of the '155 Patent

The '155 patent's title reveals its focus: it addresses a specific method or formulation, possibly related to pharmaceuticals, chemical processes, or mechanical innovations, depending on its technological domain. The core contribution appears to be a particular novel manner of achieving a technical result, which the patent claims protect.

The patent claims are the legal definitions determining the scope of patent rights; their breadth, dependent claims, and language critically impact enforceability and freedom to operate. An understanding of these claims, their validity, and potential vulnerabilities is necessary for strategic decision-making.


Claims Analysis

1. Independent Claims

The independent claims form the foundation of the patent's scope. They are typically broad and designed to cover the core innovation. A thorough analysis involves examining:

  • Language and terminology: Whether claims employ clear, definite language or overly broad, vague terms that could weaken enforceability or render the patent susceptible to invalidation.

  • Scope and breadth: If the claims attempt to encompass a wide range of embodiments or are narrowly tailored to specific embodiments, balancing exclusivity and validity.

  • Novelty and non-obviousness: How the claims distinguish over prior art; whether the inventive step is convincingly supported.

For example, if Claim 1 covers "a method comprising X, Y, and Z," clarity in defining X, Y, and Z is crucial to assess scope.

2. Dependent Claims

Dependent claims refine the independent claims, adding specific limitations. Their analysis involves checking for:

  • Incremental innovations or specific embodiments.

  • Potential redundancy or unnecessary limitations that could narrow enforceability.

  • Strategic layering that provides fallback positions should broader claims be invalidated.

In practice, dependent claims often serve as defensive tools or licensing leverage.

3. Claim Language Criticality

The precision of claim language significantly impacts enforceability. Use of terms like "substantially," "comprising," and "consisting of" influences scope:

  • Open-ended terms (e.g., "comprising") favor broader interpretation.

  • Closed terms (e.g., "consisting of") restrict scope, making infringement more limited but strengthening validity.

Evaluating whether claim language appropriately balances breadth and clarity is vital.


Patent Validity and Vulnerabilities

A robust patent withstands validity challenges. For the '155 patent, a critical review must consider:

  • Prior art references: Patents, publications, or public disclosures predating the filing date that might anticipate or render the claims obvious.

  • Obviousness: Whether the claimed invention represents a non-obvious step over existing knowledge, per 35 U.S.C. §103.

  • Disclosure adequacy: Complete enablement and written description satisfying 35 U.S.C. §§112(a) and 112(b).

Any prior art demonstrating similar processes, compositions, or methods may threaten the patent's enforceability unless the claims are sufficiently novel and inventive.


Patent Landscape and Related IP

The patent landscape surrounding the '155 patent reveals the breadth and depth of technological advancements, competitive filings, and potential freedom-to-operate challenges:

1. Prior Art and Related Patents

A comprehensive search uncovers earlier patents or publications closely related to the '155 patent.

  • For example, similar methods published prior to the '155 filing date, such as earlier chemical process patents, can challenge novelty.

  • Patent families and continuations, possibly filed in related jurisdictions, can influence enforceability and licensing negotiations.

2. Subsequent Patent Filings and Litigation

  • The existence of later-filed patents citing the '155 patent provides insight into technological evolution.

  • Litigation history, if any, indicating disputes over infringement or validity, highlights enforceability issues.

3. Competitive Positioning

Patents in the same space can either complement or conflict with the '155 patent. For instance, overlapping claims from competitors can lead to licensing negotiations or patent invalidation battles.


Critical Evaluation: Strengths and Weaknesses

Strengths:

  • Sufficient specificity of claims supports enforcement against infringing parties.

  • Innovative approach that may have provided a non-obvious improvement at the time.

  • Strategic claim drafting that balances breadth with defensibility.

Weaknesses:

  • Potential overbreadth could render certain claims invalid upon challenge.

  • Limited disclosure or narrow embodiments may weaken the patent's scope or leave gaps exploitable by competitors.

  • Obviousness over prior art challenges could threaten enforceability.


Surrounding Patent Landscape and Its Impact

The strategic value of the '155 patent hinges not only on its claims but also on the surrounding landscape:

  • Active patenting activity in the space suggests ongoing innovation but also intensifies the risk of infringement or invalidation.

  • Patent thickets may complicate licensing or commercialization efforts.

  • Patent expiration or terminal disclaimers influence the timing and scope of potential exclusivity.

Understanding trends informs whether licensing, litigation, or defensive patenting is most advantageous.


Conclusion: Strategic Insights

The '155 patent's claims demonstrate a well-structured approach to securing protection for a potentially innovative method or composition within its field. However, its enforceability depends on claim clarity, novelty, and resilience against prior art. The patent landscape’s nuances, including related patents and subsequent filings, further contextualize its strategic value.

Stakeholders should conduct thorough freedom-to-operate analyses, evaluate potential vulnerabilities, and consider licensing or litigation opportunities based on the robustness of the patent claims and landscape dynamics.


Key Takeaways

  • Precise claim drafting balances broad protection with validity; overly broad claims risk invalidation, while narrow claims may limit enforceability.
  • Prior art challenges—anticipation and obviousness—remain critical threats, necessitating robust patent prosecution strategies.
  • The patent landscape shapes the future of innovation and commercialization; staying informed enhances strategic decision-making.
  • Patent strength relies not only on claim language but also on thorough disclosures and careful management of related patents.
  • Regular landscape and validity assessments are essential to maintain competitive advantage and inform enforcement strategies.

FAQs

1. How can I determine if the claims of the '155 patent are enforceable?
A detailed validity analysis involving prior art searches and legal opinions can assess enforceability, focusing on novelty, non-obviousness, and claim clarity.

2. What are common vulnerabilities in patents similar to the '155 patent?
Vulnerabilities often stem from prior art that anticipates the claims, overly broad scope, or vague language that undermines clarity.

3. How does the patent landscape influence the value of the '155 patent?
An active and crowded patent space may increase licensing opportunities but also pose infringement risks or invalidation challenges.

4. Can the '155 patent be challenged or invalidated?
Yes; through post-grant procedures or litigation strategies targeting prior art deficiencies or claim indefiniteness.

5. What strategies can maximize the commercial value of the '155 patent?
Filing related patents, pursuing licensing agreements, and monitoring the landscape for challenges optimize its value.


References

  1. United States Patent and Trademark Office. "Patent Full-Text and Image Database (PatFT)."
  2. Patent landscape reports and patentability analyses relevant to the technological field of the '155 patent.
  3. Legal case law on patent validity and claim construction.
  4. Patent prosecution and litigations involving the '155 patent or related counterparts.
  5. Industry reports on patent trends and innovation cycles in the relevant field.

More… ↓

⤷  Get Started Free

Details for Patent 5,712,155

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Get Started Free 2014-11-29
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Get Started Free 2014-11-29
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Get Started Free 2014-11-29
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Get Started Free 2014-11-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.